Schepp W, Classen M
Dept. of Medicine II, Technical University of Munich, Germany.
Scand J Gastroenterol. 1995 Jun;30(6):511-4. doi: 10.3109/00365529509089781.
Pantoprazole is a new substituted benzimidazole that inhibits the parietal cell H+,K(+)-adenosine triphosphatase.
Pantoprazole (40 mg) was compared with ranitidine (300 mg) in the treatment of acute duodenal ulcer. Two hundred and sixty-six patients with endoscopically diagnosed duodenal ulcers entered this multicentre, double-blind study. The primary efficacy variable was complete ulcer healing at 2 weeks; treatment then continued for a further 2 weeks if ulcers were unhealed.
After 2 weeks 112 of 164 (68%) patients in the pantoprazole group had healed ulcers, compared with 36 of 81 (44%) taking ranitidine (p < 0.001). After 4 weeks the cumulative healing rates were 96% and 85% (p < 0.01). Improvement in ulcer pain was also significantly better with pantoprazole than with ranitidine (81% versus 62% with no pain at 2 weeks, p < 0.01).
Pantoprazole is clinically superior to ranitidine in the treatment of acute duodenal ulcer, in terms of both healing and symptom relief.
泮托拉唑是一种新型取代苯并咪唑，可抑制壁细胞H⁺，K⁺ - 腺苷三磷酸酶。
将泮托拉唑（40毫克）与雷尼替丁（300毫克）用于治疗急性十二指肠溃疡进行比较。266例经内镜诊断为十二指肠溃疡的患者进入了这项多中心、双盲研究。主要疗效变量为2周时溃疡完全愈合；如果溃疡未愈合，则治疗再持续2周。
2周后，泮托拉唑组164例患者中有112例（68%）溃疡愈合，而服用雷尼替丁的81例患者中有36例（44%）溃疡愈合（p<0.001）。4周后累积愈合率分别为96%和85%（p<0.01）。泮托拉唑治疗后溃疡疼痛的改善也明显优于雷尼替丁（2周时无疼痛的比例分别为81%和62%，p<0.01）。
在治疗急性十二指肠溃疡方面，无论是溃疡愈合还是症状缓解，泮托拉唑在临床上均优于雷尼替丁。
